2014 Patient Seminar (London, UK)

A Historical Perspective of HCL

Presenter:

  • Dr. Daniel Cotovsky, The Institute of Cancer Research, United Kingdom (Audio)

Update on Latest Treatment Opportunities

HCL Research at the Royal Marsden

Presenter:

Subcutaneous Cladribine

Presenter:

Vemurafenib Research

Presenter:

A Look at Quality of life

Presenter:

Patient Perspectives

Patient Story #1 (Audio)

Patient Story #2 (Audio)

Patient Story #3 (Audio)

Question and Answer Session

Is there data on treatment outcomes between patients with splenectomy versus those with it? (Audio)

Speakers:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

  • Monica Else, MA, MSc, The Institute for Cancer Research, United Kingdom

  • Dr. Enrico Tiacci, University of Perugia, Italy

Is the BRAF mutation hereditary? (Audio)

Speaker:

  • Enrico Tiacci, M.D., University of Perugia

Is the cost of treatment expensive? (Audio)

Speaker:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Should patients take precautions with blood transfusions? (Audio)

Speaker:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

What is variant HCL (HCL-v)? (Audio)

Speakers:

  • Dr. Francesco Forconi, Southampton University Hospital Trust, United Kingdom

  • Dr. Daniel Cotovsky, The Institute for Cancer Research, United Kingdom

Will there be first line therapy trials with Vemurafenib? (Audio)

Speaker:

  • Dr. Enrico Tiacci, University of Perugia, Italy

Should other drugs with less toxicity than Cladribine and Pentostatin be considered as a first line therapy? (Audio)

Speakers:

  • Dr. Enrico Tiacci, University of Perugia, Italy

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom

Is skin cancer correlated with treatment? (Audio)

Speaker:

  • Dr. Claire Dearden, The Royal Marsden, United Kingdom